Literature DB >> 28666070

Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis.

Byung Seok Kim1, Yeon Seok Seo2, Young Seok Kim3, Chang Hyeong Lee1, Han Ah Lee2, Soon Ho Um2, Jeong-Ju Yoo3, Sang Gyune Kim3, Sang Jun Suh4, Young Kul Jung4, Sang Hoon Ahn5, Kwang-Hyub Han5, Hyung Joon Yim4, Seung Up Kim5.   

Abstract

BACKGROUND AND AIM: A subcirrhotic range of liver stiffness (sc-LS), assessed by transient elastography, is associated with better outcomes in patients with chronic hepatitis B (CHB). We investigated whether the achievement of sc-LS by antiviral therapy (AVT) reduced the risk of developing hepatocellular carcinoma (HCC) in patients with CHB-related advanced fibrosis or cirrhosis.
METHODS: In total, 209 patients with CHB-related advanced fibrosis or cirrhosis, who received paired transient elastography examinations during AVT between 2007 and 2012, were enrolled. The cut-off LS value for ultrasonographic cirrhosis was defined as 11.6 kPa.
RESULTS: The median age of the study population was 51 years, with males predominating (n = 138, 66.0%). The median LS value at enrollment was 14.1 kPa (interquartile range: 9.5-24.1 kPa). After 2 years of AVT, 140 (67.0%) patients achieved sc-LS. During the study period, 28 (13.4%) patients developed HCC after 2 years of AVT. On multivariate analysis, the achievement of sc-LS after AVT was independently associated with a decreased risk of HCC development (hazard ratio [HR] = 0.485, P = 0.047), whereas older age (HR = 1.071) and male gender (HR = 3.704) were independently associated with an increased HCC risk (both P < 0.05). Patients with a cirrhotic range of LS value after 2 years of AVT were at a higher risk of HCC development than those with sc-LS (log-rank test, P = 0.020).
CONCLUSIONS: The achievement of sc-LS after AVT can reduce the risk of HCC development in patients with CHB, even when advanced fibrosis or cirrhosis is apparent on starting AVT.
© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  antiviral therapy; cirrhosis; hepatitis B; hepatocellular carcinoma; liver fibrosis; liver stiffness; transient elastography

Mesh:

Substances:

Year:  2018        PMID: 28666070     DOI: 10.1111/jgh.13854

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  3 in total

1.  Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B.

Authors:  Ho Soo Chun; Jae Seung Lee; Hye Won Lee; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Seung Up Kim
Journal:  Dig Dis Sci       Date:  2021-09-02       Impact factor: 3.487

2.  The Age, Gamma-Glutamyl Transpeptidase and Platelet Index: A Novel Noninvasive Model for Predicting Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Related Liver Cirrhosis.

Authors:  Kai Liu; Zeyu Huang; Suhua Yang; Lin Lin; Shuqin Zheng; Xiujun Zhang; Yuan Xue; Weibin Xie
Journal:  J Hepatocell Carcinoma       Date:  2022-10-08

Review 3.  Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update.

Authors:  James Lok; Kosh Agarwal
Journal:  Viruses       Date:  2021-07-10       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.